Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Nov. 15 '25)

Image
By G.M.

 


    Arch Virol

  1. WANG P, Fu J, Wu H, Zhu L, et al
    Amino acid substitutions associated with adaptation of novel H10N3 and H10N5 avian influenza viruses to mice.
    Arch Virol. 2025;170:242.
    PubMed        


    Drug Saf

  2. WONG J, Donegan K, Harrison K, Jan T, et al
    Implementation and Results of Active Vaccine Safety Monitoring During the COVID-19 Pandemic in the UK: A Regulatory Perspective.
    Drug Saf. 2025;48:1365-1385.
    PubMed         Abstract available

  3. VAN HOLLE L
    Observed Versus Expected Analysis-How Does It Fit in the Pharmacovigilance Toolkit?
    Drug Saf. 2025;48:1325-1330.
    PubMed         Abstract available


    Drugs

  4. LEE A
    Onradivir: First Approval.
    Drugs. 2025;85:1609-1612.
    PubMed         Abstract available


    J Clin Microbiol

  5. HOGAN CA, Le AT, Khan A, Su LD, et al
    Comprehensive metabolomics combined with machine learning for the identification of SARS-CoV-2 and other viruses directly from upper respiratory samples.
    J Clin Microbiol. 2025;63:e0204224.
    PubMed         Abstract available


    J Gen Virol

  6. GIOVANETTI M, Cella E, Soliani L, Prosperi A, et al
    From North to South: transmission dynamics of H1N1pdm09 swine influenza A viruses in Italy.
    J Gen Virol. 2025;106.
    PubMed         Abstract available


    J Infect

  7. CRAWFORD-JONES D, Charlett M, Downs L, Jeffery K, et al
    Real-world utility of antigen-based testing (LumiraDX) for SARS-CoV-2 and influenza A/B in an acute hospital emergency care setting: a useful triage tool.
    J Infect. 2025;91:106649.
    PubMed        


    J Infect Dis

  8. BUCHAN SA, Alessandrini J, Drover SSM, Andrew MK, et al
    Incidence of Respiratory Syncytial Virus-Associated Hospitalization Among Adults in Ontario, Canada, 2017-2019.
    J Infect Dis. 2025;232:e799-e810.
    PubMed         Abstract available

  9. DESCHENES NM, Perez-Vargas J, Zhong Z, Thomas M, et al
    Functional and structural characterization of treatment-emergent nirmatrelvir resistance mutations at low frequencies in the main protease (Mpro) reveals a unique evolutionary route for SARS-CoV-2 to gain resistance.
    J Infect Dis. 2025 Jun 3:jiaf294. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  10. NAITO T, Ushirogawa H, Kunishio M, Yano H, et al
    Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant.
    J Virol. 2025 Nov 13:e0139025. doi: 10.1128/jvi.01390.
    PubMed         Abstract available

  11. JUNG KI, Xia C, McKenna S, He Y, et al
    Ceramide synthase 4 interferes with replication of influenza virus but is downregulated by infection.
    J Virol. 2025 Nov 11:e0156325. doi: 10.1128/jvi.01563.
    PubMed         Abstract available


    J Virol Methods

  12. KOPETZKY J, Mansour SC, Floyd R, Byrne L, et al
    Development and Evaluation of a Molecular Assay for the Detection and Quantification of SARS-CoV-2, influenza A, influenza B, and Respiratory Syncytial Virus from Municipal Wastewater in British Columbia.
    J Virol Methods. 2025 Nov 5:115297. doi: 10.1016/j.jviromet.2025.115297.
    PubMed         Abstract available


    Lancet

  13. REHM J, Assanangkornchai S, Hendershot CS, Franklin A, et al
    Alcohol use disorders.
    Lancet. 2025 Oct 9:S0140-6736(25)01496-5. doi: 10.1016/S0140-6736(25)01496.
    PubMed         Abstract available


    PLoS Comput Biol

  14. ROY M, Clapham HE, Mishra S
    Incorporating human mobility to enhance epidemic response and estimate real-time reproduction numbers.
    PLoS Comput Biol. 2025;21:e1013642.
    PubMed         Abstract available


    PLoS One

  15. FU K, Jackson DB, Testa A
    Adverse childhood experiences and COVID-19 vaccination uptake: Examining the intersection of sex and urban-rural residence.
    PLoS One. 2025;20:e0336390.
    PubMed         Abstract available

  16. POURSHABAN M, Allahbakhshian A, Hasankhani H
    Fading connections: A phenomenological study of oncology nurses' experiences of Missed Nursing Care during an infectious disease outbreak.
    PLoS One. 2025;20:e0336174.
    PubMed         Abstract available

  17. BASU S
    On the mechanics of inhaled bronchial transmission of pathogenic microdroplets generated from the upper respiratory tract, with implications for downwind infection onset.
    PLoS One. 2025;20:e0335962.
    PubMed         Abstract available

  18. BERKE A, Calacci D, Pentland A, Larson K, et al
    Evaluating Amazon effects and the limited impact of COVID-19 with purchases crowdsourced from US consumers.
    PLoS One. 2025;20:e0336571.
    PubMed         Abstract available

  19. LEE HK, Choi JY, Park JH, Chang MH, et al
    SARS-CoV-2 spike protein causes synaptic dysfunction and p-tau and alpha-synuclein aggregation leading cognitive impairment: The protective role of metformin.
    PLoS One. 2025;20:e0336015.
    PubMed         Abstract available

  20. MOORE TR, Chusan YAC, Sanderson E, Calancie L, et al
    Community-led change: Progress toward policy, systems, and environmental impacts through the Catalyzing Communities initiative.
    PLoS One. 2025;20:e0336482.
    PubMed         Abstract available

  21. BONTEMPS AP, Pridgen BE, Wagner WP, Cropsey KL, et al
    A national study of substance use: Demonstrated use of recommendations for best practice online data collection.
    PLoS One. 2025;20:e0336612.
    PubMed         Abstract available

  22. PANDA R, Mukherjee R, Singh K, Lahoti S, et al
    Effects of the ECHO tele-mentoring program on Long COVID management in health facilities in India: A mixed-methods evaluation.
    PLoS One. 2025;20:e0331293.
    PubMed         Abstract available

  23. OYEGUN EI, Ategbole M, Jorgensen C, Fisher A, et al
    Factors associated with knowledge, attitudes, and behaviors regarding antiviral medications for COVID-19 among US adults.
    PLoS One. 2025;20:e0335182.
    PubMed         Abstract available

  24. NIKAEIN K, Kanannejad Z, Ghatee MA
    Geographical and climatic risk factors for COVID-19 in southwest Iran during the 2020-2021 epidemic.
    PLoS One. 2025;20:e0336595.
    PubMed         Abstract available

  25. KUMAR L, Ahmed I, Kumari C, Nasir N, et al
    Factors associated with prolonged viral shedding in COVID-19 infection: A retrospective cohort from Karachi, Pakistan.
    PLoS One. 2025;20:e0336774.
    PubMed         Abstract available

  26. CORNWELL B, Ji S, Henderson SG, Meredith G, et al
    Amplification of the power of network hubs and degree skewness over infectious disease spread during lulls.
    PLoS One. 2025;20:e0322687.
    PubMed         Abstract available

  27. LU M, Bu Z, Xiang N, Yu J, et al
    Association between COVID-19 vaccination and atopic diseases in US adults: A retrospective cohort study.
    PLoS One. 2025;20:e0336698.
    PubMed         Abstract available

  28. SHARMIN E, Khan AI, Ahmed SF
    Clinical assessment of transplacental transfer of maternal SARS-CoV-2 IgG antibodies against spike and nucleocapsid proteins: A chemiluminescence microparticle immunoassay study.
    PLoS One. 2025;20:e0336516.
    PubMed         Abstract available

  29. PHOMMASONE K, Souksakhone C, Chanthongthip A, Phonemixay O, et al
    Nationwide seroprevalence of SARS-CoV-2 during the COVID-19 pandemic and prepandemic periods in Lao PDR.
    PLoS One. 2025;20:e0336239.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  30. BI K, Bandekar SR, Bouchnita A, Cramer A, et al
    Estimated impact of 2022-2023 influenza vaccines on annual hospital burden in the United States.
    Proc Natl Acad Sci U S A. 2025;122:e2505175122.
    PubMed         Abstract available


    Vaccine

  31. REEKIE J, Stepien S, Hendry A, Dalton L, et al
    Provider setting for influenza and COVID-19 vaccination among Australian adults in 2023 and 2024.
    Vaccine. 2025;68:127945.
    PubMed         Abstract available

  32. CHENG C, Chen X, Ge Y, Sung MH, et al
    Assessing factors associated with one-year antibody waning in participants with repeated influenza vaccinations: A six-year cohort study.
    Vaccine. 2025;68:127904.
    PubMed         Abstract available

  33. ZHU Y, Si M, Wang L, Zhang Y, et al
    Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial.
    Vaccine. 2025;68:127962.
    PubMed         Abstract available

  34. JEFFERY C, Cheyne CP, Buchan I, Garcia-Finana M, et al
    Effect of influenza vaccination on post-admission outcomes for influenza patients in England: a population-based cohort study.
    Vaccine. 2025;68:127933.
    PubMed         Abstract available

  35. DENG L, Fan X, Li J, Yin D, et al
    Characteristics of neuraminidase-specific immune responses in influenza vaccinated or naturally infected populations in Shenzhen, China.
    Vaccine. 2025;69:127918.
    PubMed         Abstract available

  36. DO THT, Kent SJ, Whealtey AK, Koutsakos M, et al
    Impact of serum versus anticoagulant-containing plasma on influenza virus neuraminidase-based serological assays.
    Vaccine. 2025;69:127956.
    PubMed         Abstract available


    Virology

  37. SEEKINGS AH, Billington E, Mahmood S, Thomas SS, et al
    Infection of point-of-lay hens to assess the sequential events during H7N7 high-pathogenicity avian influenza emergence at a layer premises.
    Virology. 2025;614:110733.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »